UTA CP2 NURS 5338 FINAL EXAM – QUESTIONS AND ANSWERS | VERIFIED AND WELL DETAILED ANSWERS |
PLUS RATIONALES | GUARANTEED PASS | LATEST EXAM UPDATE
Core Domains:
- Advanced Pharmacokinetics and Pharmacodynamics
- Autonomic and Central Nervous System Pharmacology
- Cardiovascular and Renal Pharmacology
- Endocrine and Metabolic Pharmacology
- Antimicrobial and Anti-infective Therapy
- Pain Management and Opioid Prescribing
- Special Populations (Pediatric, Geriatric, Pregnancy)
- Evidence-Based Prescribing, Safety, and Regulatory Compliance
- Health Promotion, Screening, and Disease Prevention
Introduction
This comprehensive examination is designed to rigorously assess the advanced practice nursing student's mastery of
pharmacotherapeutics and clinical decision-making as required for the UTA CP2 NURS 5338 final evaluation. The
exam encompasses foundational theory, applied clinical knowledge, and critical thinking skills necessary for safe and
effective prescribing. It includes a range of multiple-choice and scenario-based questions that emphasize real-world
application, regulatory compliance, and ethical standards. By covering key domains such as pharmacokinetics, drug
therapy for chronic conditions, and management of special populations, this assessment ensures the student is
prepared to deliver high-quality, evidence-based patient care. This document serves as a definitive study resource,
providing verified answers and detailed rationales to facilitate learning and ensure success.
,SECTION ONE: QUESTIONS 1–100
Question 1
An APRN is prescribing a medication that is a weak acid with a pKa of 4.5. In which body compartment will this drug
primarily be absorbed?
A. Stomach (pH 1.5–2.0)
B. Small intestine (pH 6.0–7.5)
C. Blood (pH 7.35–7.45)
D. Urine (pH 5.0–8.0)
🟢 A. Stomach (pH 1.5–2.0)
🔴 Explanation: Weak acids are non-ionized and lipid-soluble in acidic environments, favoring absorption. Using the
Henderson-Hasselbalch equation, when the pH is less than the pKa, the acidic drug is predominantly non-ionized,
allowing it to cross membranes readily. The stomach's acidic pH is below the drug's pKa of 4.5, making it the primary
site of absorption .
Question 2
A patient is taking two drugs that are highly protein-bound (98% each). Which pharmacokinetic phenomenon is
most likely to occur?
A. Decreased drug half-life
B. Drug displacement and increased free drug concentration
C. Increased renal excretion
D. Decreased volume of distribution
🟢 B. Drug displacement and increased free drug concentration
🔴 Explanation: Highly protein-bound drugs compete for binding sites on plasma proteins like albumin. When two
,such drugs are administered, one can displace the other, increasing the free (unbound) concentration of the
displaced drug. This can lead to heightened pharmacologic effects and potential toxicity .
Question 3
A patient with cirrhosis has impaired liver function. Which pharmacokinetic process is most directly affected?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion
🟢 C. Metabolism
🔴 Explanation: The liver is the primary site of drug metabolism (biotransformation). In cirrhosis, hepatic blood flow
and enzyme activity are reduced, decreasing the clearance of many drugs and prolonging their half-life,
necessitating dose adjustments .
Question 4
A drug has a half-life of 4 hours. Approximately how long will it take for the drug to reach steady-state?
A. 8 hours
B. 12 hours
C. 20 hours
D. 40 hours
🟢 C. 20 hours
🔴 Explanation: Steady-state is reached after approximately 4–5 half-lives. With a 4-hour half-life, steady-state is
achieved in about 20 hours (5 × 4 hours). This principle is crucial for understanding how long it takes for a drug's
concentration to stabilize .
, Question 5
A medication with a narrow therapeutic index (NTI) requires:
A. A wide margin of safety
B. Small changes in dose can lead to toxicity or inefficacy
C. Only available intravenously
D. No side effects
🟢 B. Small changes in dose can lead to toxicity or inefficacy
🔴 Explanation: NTI drugs have a narrow window between the minimum effective concentration (MEC) and the
minimum toxic concentration (MTC). Small dose adjustments can cause significant changes in drug levels, leading to
either subtherapeutic effects or toxicity. Therapeutic drug monitoring (TDM) is essential for medications like warfarin
and digoxin .
Question 6
Which phase of drug metabolism involves conjugation reactions (e.g., glucuronidation, sulfation)?
A. Phase I (oxidation, reduction, hydrolysis)
B. Phase II (conjugation)
C. Phase III (excretion)
D. Absorption phase
🟢 B. Phase II (conjugation)
🔴 Explanation: Phase II metabolism involves conjugation, where a polar group like glucuronide or sulfate is added
to the drug or its Phase I metabolite, making it more water-soluble and easier to excrete in urine or bile. This process
is catalyzed by transferase enzymes .
Question 7
A drug that is a strong CYP3A4 inducer would be expected to:
A. Increase the levels of other drugs metabolized by CYP3A4
PLUS RATIONALES | GUARANTEED PASS | LATEST EXAM UPDATE
Core Domains:
- Advanced Pharmacokinetics and Pharmacodynamics
- Autonomic and Central Nervous System Pharmacology
- Cardiovascular and Renal Pharmacology
- Endocrine and Metabolic Pharmacology
- Antimicrobial and Anti-infective Therapy
- Pain Management and Opioid Prescribing
- Special Populations (Pediatric, Geriatric, Pregnancy)
- Evidence-Based Prescribing, Safety, and Regulatory Compliance
- Health Promotion, Screening, and Disease Prevention
Introduction
This comprehensive examination is designed to rigorously assess the advanced practice nursing student's mastery of
pharmacotherapeutics and clinical decision-making as required for the UTA CP2 NURS 5338 final evaluation. The
exam encompasses foundational theory, applied clinical knowledge, and critical thinking skills necessary for safe and
effective prescribing. It includes a range of multiple-choice and scenario-based questions that emphasize real-world
application, regulatory compliance, and ethical standards. By covering key domains such as pharmacokinetics, drug
therapy for chronic conditions, and management of special populations, this assessment ensures the student is
prepared to deliver high-quality, evidence-based patient care. This document serves as a definitive study resource,
providing verified answers and detailed rationales to facilitate learning and ensure success.
,SECTION ONE: QUESTIONS 1–100
Question 1
An APRN is prescribing a medication that is a weak acid with a pKa of 4.5. In which body compartment will this drug
primarily be absorbed?
A. Stomach (pH 1.5–2.0)
B. Small intestine (pH 6.0–7.5)
C. Blood (pH 7.35–7.45)
D. Urine (pH 5.0–8.0)
🟢 A. Stomach (pH 1.5–2.0)
🔴 Explanation: Weak acids are non-ionized and lipid-soluble in acidic environments, favoring absorption. Using the
Henderson-Hasselbalch equation, when the pH is less than the pKa, the acidic drug is predominantly non-ionized,
allowing it to cross membranes readily. The stomach's acidic pH is below the drug's pKa of 4.5, making it the primary
site of absorption .
Question 2
A patient is taking two drugs that are highly protein-bound (98% each). Which pharmacokinetic phenomenon is
most likely to occur?
A. Decreased drug half-life
B. Drug displacement and increased free drug concentration
C. Increased renal excretion
D. Decreased volume of distribution
🟢 B. Drug displacement and increased free drug concentration
🔴 Explanation: Highly protein-bound drugs compete for binding sites on plasma proteins like albumin. When two
,such drugs are administered, one can displace the other, increasing the free (unbound) concentration of the
displaced drug. This can lead to heightened pharmacologic effects and potential toxicity .
Question 3
A patient with cirrhosis has impaired liver function. Which pharmacokinetic process is most directly affected?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion
🟢 C. Metabolism
🔴 Explanation: The liver is the primary site of drug metabolism (biotransformation). In cirrhosis, hepatic blood flow
and enzyme activity are reduced, decreasing the clearance of many drugs and prolonging their half-life,
necessitating dose adjustments .
Question 4
A drug has a half-life of 4 hours. Approximately how long will it take for the drug to reach steady-state?
A. 8 hours
B. 12 hours
C. 20 hours
D. 40 hours
🟢 C. 20 hours
🔴 Explanation: Steady-state is reached after approximately 4–5 half-lives. With a 4-hour half-life, steady-state is
achieved in about 20 hours (5 × 4 hours). This principle is crucial for understanding how long it takes for a drug's
concentration to stabilize .
, Question 5
A medication with a narrow therapeutic index (NTI) requires:
A. A wide margin of safety
B. Small changes in dose can lead to toxicity or inefficacy
C. Only available intravenously
D. No side effects
🟢 B. Small changes in dose can lead to toxicity or inefficacy
🔴 Explanation: NTI drugs have a narrow window between the minimum effective concentration (MEC) and the
minimum toxic concentration (MTC). Small dose adjustments can cause significant changes in drug levels, leading to
either subtherapeutic effects or toxicity. Therapeutic drug monitoring (TDM) is essential for medications like warfarin
and digoxin .
Question 6
Which phase of drug metabolism involves conjugation reactions (e.g., glucuronidation, sulfation)?
A. Phase I (oxidation, reduction, hydrolysis)
B. Phase II (conjugation)
C. Phase III (excretion)
D. Absorption phase
🟢 B. Phase II (conjugation)
🔴 Explanation: Phase II metabolism involves conjugation, where a polar group like glucuronide or sulfate is added
to the drug or its Phase I metabolite, making it more water-soluble and easier to excrete in urine or bile. This process
is catalyzed by transferase enzymes .
Question 7
A drug that is a strong CYP3A4 inducer would be expected to:
A. Increase the levels of other drugs metabolized by CYP3A4
